Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors

Metastatic Breast Cancer Clinical Trial

Official title:

Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01640665
• Other study ID #: GC0212
• Status: Completed
• Phase: Phase 1
• First received: June 5, 2012
• Last updated: September 15, 2016
• Start date: July 2012
• Est. completion date: August 2014

Study information

• Verified date: September 2016
• Source: Yale University
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to find the maximum tolerated dose of the combination of two drugs. The two drugs are Sorafenib and Capecitabine. The drug Sorafenib is an approved drug which is used to treat certain cancers. The drug Capecitabine is approved to treat patients with advanced breast cancer as well as early stage colon cancer.

Description:

This is a pilot study of Sorafenib combined with Capecitabine in patients with histologically confirmed unresectable or metastatic breast and GI tumors. One cycle will consist of 4 weeks of treatment. The dose of Sorafenib will be 600 mg administered orally daily in divided doses. Capecitabine will be given at a fixed dose of 2000 mg orally BID x 7 days every 14 days

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: August 2014
• Est. primary completion date: August 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age = 18 years.

• Life expectancy of at least 12 weeks (3 months).

• ECOG Performance Status 0 or 1.

• Histologically confirmed unresectable or metastatic breast and/or GI tumors for which curative standard treatments are unavailable

• Adequate bone marrow, liver and renal function as assessed by the following:

• Hemoglobin > 9.0 g/dl

• Absolute neutrophil count (ANC) >1,500/mm3

• Platelet count > 100,000/mm3

• Total bilirubin < 1.5 times ULN

• ALT and AST < 2.5 times the ULN ( < 5 x ULN for patients with liver involvement)

• GFR > 30 ml/min

• All acute toxic effects (excluding alopecia and neuropathy) of any prior treatment have resolved to NCI-CTCAE v4.0 Grade 1 or less at the time of signing the Informed Consent Form (ICF).

• Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of study drug. Post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy test.

• Subjects (men and women) of childbearing potential must agree to use adequate contraception beginning at the signing of the ICF until at least 30 days after the last dose of study drug. The definition of adequate contraception will be based on the judgment of the principal investigator or a designated associate.

• Subject must be able to swallow and retain oral medication.

• Subjects must be able to understand and be willing to sign the written informed consent form. A signed informed consent form must be appropriately obtained prior to the conduct of any trial-specific procedure.

Exclusion Criteria:

• Metastatic brain or meningeal tumors (unless subject completed definitive therapy more than 1 month previously and is stable off steroids).

• Uncontrolled hypertension defined as systolic blood pressure > 140 mmHg or diastolic pressure > 90 mmHg, despite optimal medical management.

• Active or clinically significant cardiac disease including:

• Congestive heart failure - New York Heart Association (NYHA) > Class II.

• Active coronary artery disease.

• Cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin.

• Unstable angina (anginal symptoms at rest), new-onset angina within 3 months before randomization, or myocardial infarction within 6 months before randomization.

• Subject with any pulmonary hemorrhage/bleeding event of NCI-CTCAE v4.0 Grade 2 or higher within 4 weeks of study enrollment; any other hemorrhage/bleeding event of NCI-CTCAE v4.0 Grade 3 or higher within 4 weeks of study enrollment.

• Major surgery, open biopsy or significant traumatic injury within 30 days of first study drug.

• Presence of an active non-healing wound, non-healing ulcer, or bone fracture.

• Thrombotic or embolic events such as a cerebrovascular accident (including transient ischemic attacks) within 3 month of informed consent.

• Anticoagulation with warfarin is not permitted.

• Evidence or history of bleeding diathesis or coagulopathy.

• Subjects who have used strong CYP3A4 inducers (eg, phenytoin, carbamazepine, phenobarbital, St. John's Wort [Hypericum perforatum], dexamethasone at a dose of greater than 16 mg daily, or rifampin [rifampicin], and/or rifabutin) within 30 days of trial enrollment.

• Subjects with a history of dihydopyrimidine dehydrogenase (DHPD) deficiency or severe and unexpected reactions to fluropyrimidines.

• Subjects with any previously untreated or concurrent cancer that is distinct in primary site or histology except cervical cancer in-situ, treated basal cell carcinoma, or superficial bladder tumor. Subjects surviving a cancer that was curatively treated and without evidence of disease for more than 3 years before randomization are allowed. All relevant cancer treatments must be completed at least 3 years prior to study entry (i.e., signature date of the informed consent form).

• History of organ allograft. (Including corneal transplant).

• Known human immunodeficiency virus (HIV) infection or Hepatitis B or C currently undergoing active antiviral treatment.

• Any malabsorption problem.

• Anticancer chemotherapy or immunotherapy during the study is not permitted.

• Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial.

• Women who are pregnant or breast-feeding.

• Inability to comply with the protocol and/or not willing or not available for follow-up assessments.

• Any condition which, in the investigator's opinion, makes the subject unsuitable for trial participation.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Breast Neoplasms
• Digestive System Neoplasms
• Gastrointestinal Neoplasms
• Gastrointestinal Tumors
• Metastatic Breast Cancer

Intervention

Drug:
• Sorafenib
One cycle will consist of 4 weeks of treatment. The dose of Sorafenib will be 600 mg administered orally daily in divided doses.
• Capecitabine
Capecitabine will be given at a fixed dose of 2000 mg orally BID x 7 days every 14 days.

Locations

Country	Name	City	State
United States	Yale Cancer Center	New Haven	Connecticut

Sponsors (2)

Lead Sponsor	Collaborator
Yale University	Bayer

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum Tolerated Dose / Safety	Primary Objectives: Safety; Determination of maximum tolerated dose	4 weeks	Yes
Secondary	Response	Secondary Objectives: Overall Response Rate; Duration of Response	8 Weeks	No

External Links

•   Yale Cancer Center Website